IP Library Granted Patent US 7,119,119
Granted Patent B2
US 7,119,119 · App. 11/144,093 · Granted Oct 10, 2006

Immunoregulatory compounds and derivatives and methods of treating diseases therewith

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,119,119
App. No.
11/144,093
Granted
Oct 10, 2006
Kind
B2
Abstract

Compounds are disclosed having the structure of Formula I: where R 1 , R 3 , and R 4 are independently hydrogen or C 1 to C 4 alkyl, and R 2 is: where R 5 is selected from the group consisting of hydrogen and C 1 to C 4 alkyl, or where R 6 , R 7 and R 8 are independently hydrogen or C 1 to C 4 alkyl; or the esters or pharmacologically acceptable salts thereof. Such compounds may be utilized for the prophylaxis or treatment of various diseases, particularly inflammatory conditions of the GI tract. Methods of treating inflammatory conditions of the GI tract such as inflammatory bowel disease using compounds having the following formula are also disclosed: where R 9 , R 10 and R 11 are independently selected from the group consisting of hydrogen and C 1 to C 4 alkyl, and R 12 is selected from the group consisting of hydrogen and —C(O)R 13 , where R 13 is a C 1 to C 6 alkyl or an aryl group.

Claims (5)

1. A pharmaceutical composition for treating an inflammatory condition of the gastrointestinal tract in a subject in need of such treatment, the composition comprising a 4-aminophenylacetic acid and/or ester or pharmaceutically acceptable salt thereof and a 5-aminosalicylic acid and/or ester or pharmaceutically acceptable salt thereof.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition when administered to a subject in need thereof results in treatment of ulcerative colitis.

3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition when administered to a subject in need thereof results in treatment of Crohn's disease.

4. The pharmaceutical composition of claim 1 , wherein the composition is formulated for oral administration.

5. The pharmaceutical composition of claim 1 , wherein the composition is formulated for rectal administration.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2019
From: EKWURIBE, NNOCHIRI NKEM; RIGGS-SAUTHIER, JENNIFER A
To: NOBEX CORPORATION
Reel/Frame 049199/0278 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2019
From: RIGGS-SAUTHIER, JENNIFER A; NNOCHIRI, EKWURIBE N
To: NOBEX CORPORATION
Reel/Frame 049186/0479 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2006
From: NOBEX CORPORATION
To: BIOCON LIMITED
Reel/Frame 017555/0904 →